Quarterly report [Sections 13 or 15(d)]

Significant Agreements (Details)

v3.26.1
Significant Agreements (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 01, 2023
Jul. 14, 2022
Jul. 13, 2021
Oct. 31, 2017
Sep. 30, 2018
Mar. 31, 2026
Mar. 31, 2025
Sep. 30, 2021
Feb. 28, 2023
Aug. 31, 2022
Significant Agreements [Line Items]                    
Agreement due payments       $ 1,650            
Second clinical trial payment       $ 50            
Net sales percentage       2.00%            
Common stock valued           $ 19,569 $ 2,707      
Anti-dilution shares of common stock (in Shares)           18,796,272 10,220,673      
Milestone payments $ 3,700                  
Lotus International Pte Ltd [Member]                    
Significant Agreements [Line Items]                    
Sublicense income percentage           20.00%        
Lee’s Pharmaceutical (HK) Limited [Member]                    
Significant Agreements [Line Items]                    
Significant payment received   $ 1,000                
Milestone payments   $ 1,000                
Lotus International Pte Ltd [Member]                    
Significant Agreements [Line Items]                    
Significant payment received $ 700                  
Shilpa Medicare Ltd [Member]                    
Significant Agreements [Line Items]                    
Payment amount           $ 4,500        
Exclusive license agreement [Member]                    
Significant Agreements [Line Items]                    
Agreement due payments       $ 50            
Spectrum Agreement [Member]                    
Significant Agreements [Line Items]                    
Issued of common shares (in Shares)         31,366          
Common stock valued         $ 4          
Public market capitalization     $ 50,000   $ 50,000          
Research and development expenses               $ 2,200    
Sublicense income granted percentage         40.00%          
Sublicense income percentage         20.00%          
Spectrum Agreement [Member] | Common Stock [Member]                    
Significant Agreements [Line Items]                    
Anti-dilution shares of common stock (in Shares)     43,838              
Spectrum Agreement [Member] | Investment [Member]                    
Significant Agreements [Line Items]                    
Interest on ownership         4.00%          
Spectrum Agreement [Member] | Altair Nanomaterials, Inc [Member]                    
Significant Agreements [Line Items]                    
Required to pay               200    
Spectrum Agreement [Member] | Altair [Member]                    
Significant Agreements [Line Items]                    
Required to pay               $ 4,500    
Sublicense Development Agreement [Member]                    
Significant Agreements [Line Items]                    
Significant payment received                 $ 700 $ 1,000
Minimum [Member]                    
Significant Agreements [Line Items]                    
Royalties percentage   7.00%                
Maximum [Member]                    
Significant Agreements [Line Items]                    
Royalties percentage   10.00%